In this video, Brenton Flynn describes Questcor Pharmaceuticals' primary opportunity. It's a drug called Acthar, a long acting gel that slowly releases a natural hormone called ACTH. Even though ACTH was approved 60 years ago, Questcor has seen sales of Acthar double this past year, with a projected earnings growth of 20% for the upcoming year. Selling at less than 7.5 times future earnings and paying a 3% dividend, Questcor looks like an attractive value stock.
- Feb 20, 2013 at 10:13AM
- Health Care